195 related articles for article (PubMed ID: 19747139)
21. Matrix metalloproteinases: new directions toward inhibition in the fight against cancers.
King SE
Future Med Chem; 2016; 8(3):297-309. PubMed ID: 26910530
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
23. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
Li X; Wu JF
Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
[TBL] [Abstract][Full Text] [Related]
24. Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke RE; Libert C
Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
[TBL] [Abstract][Full Text] [Related]
25. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment.
Stellas D; Patsavoudi E
Anticancer Agents Med Chem; 2012 Sep; 12(7):707-17. PubMed ID: 22292747
[TBL] [Abstract][Full Text] [Related]
27. Hydroxamic acids as matrix metalloproteinase inhibitors.
Verma RP
Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
Fischer T; Riedl R
Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
Fingleton B
Expert Opin Ther Targets; 2003 Jun; 7(3):385-97. PubMed ID: 12783574
[TBL] [Abstract][Full Text] [Related]
30. [Metalloproteinases. Structure and function].
Lipka D; Boratyński J
Postepy Hig Med Dosw (Online); 2008 Jul; 62():328-36. PubMed ID: 18614970
[TBL] [Abstract][Full Text] [Related]
31. MMP inhibitors in cardiac diseases: an update.
Dormán G; Kocsis-Szommer K; Spadoni C; Ferdinandy P
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):186-94. PubMed ID: 18221118
[TBL] [Abstract][Full Text] [Related]
32. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
33. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloprotease inhibitors: design from structure.
Borkakoti N
Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
[TBL] [Abstract][Full Text] [Related]
35. Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020).
Lenci E; Cosottini L; Trabocchi A
Expert Opin Ther Pat; 2021 Jun; 31(6):509-523. PubMed ID: 33487088
[No Abstract] [Full Text] [Related]
36. Matrix metalloproteinases and their clinical applications in orthopaedics.
Bramono DS; Richmond JC; Weitzel PP; Kaplan DL; Altman GH
Clin Orthop Relat Res; 2004 Nov; (428):272-85. PubMed ID: 15534553
[TBL] [Abstract][Full Text] [Related]
37. Status of research on matrix metalloproteinases (MMPs) in India.
Bulbule A; Saraswati S; Kundu GC
Expert Opin Ther Targets; 2011 Jun; 15(6):671-5. PubMed ID: 21476880
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases.
Zitka O; Kukacka J; Krizkova S; Huska D; Adam V; Masarik M; Prusa R; Kizek R
Curr Med Chem; 2010; 17(31):3751-68. PubMed ID: 20846107
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
40. MMP-2 selectivity in hydroxamate-type inhibitors.
Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
